- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$14.22 BnMarket Estimate, 2026
$15.53 BnMarket Forecast, 2034
$31.36 BnCAGR, 2026–2034
9.18%Asia Pacific Cardiovascular Devices Market Size
The Asia Pacific cardiovascular devices market size was valued at USD 14.22 billion in 2025 and is anticipated to reach USD 15.53 billion in 2026 from USD 31.36 billion by 2034, growing at a CAGR of 9.18% during the forecast period from 2026 to 2034
The APAC regional market growth for cardiovascular devices is projected to be driven by the factors such as the increasing prevalence of cardiovascular diseases and the growing population across the region. The senior population is more associated with cardiovascular diseases. Therefore, the rising prevalence of these diseases in emerging countries such as China and India significantly contributes to the region's market growth. For instance, according to the Global Burden of Disease, nearly a quarter (24.8 percent) of all deaths in India is due to CVDs.
Lack of exercise and a poor diet, such as a high-fat, high-calorie diet, raise the risk of cardiovascular disease (CVD). Obesity affects 18.5 percent of children aged 2 to 19 years. At the same time, overall obesity rates continue to be greater than a generation ago. Therefore, lack of exercise, an unhealthy diet, and a significant increase in the obese population are projected to increase cardiovascular disease in the region's population.
Cardiovascular disease (CVD) is the primary cause of death in China, posing a significant burden. Approximately 106 million CVD patients in China, with 33 million suffering from a stroke; this study provides disease control and prevention data by presenting the most recent cardiovascular mortality in China in 2019.
On the other hand, factors such as expanding population, adopting sedentary lifestyles, and rising obesity incidence impact market growth. Obesity is a significant problem that affects people of all ages and income levels. Obesity and overweight refer to improper or excessive fat accumulation in the body, which causes health problems that lead to cardiovascular diseases, thereby influencing the demand for market growth.
Furthermore, the regional players' increasing acquisitions, mergers, and collaborations significantly expand the APAC regional market growth. Additionally, growing investments and funding by the government and non-government organizations for R&D, product advancements, and infrastructure improvement in this region support market growth.
On the other hand, the cardiovascular devices market in the APAC region is expected to be restrained by the factors such as the unavailability of skilled professionals and limited financial resources in some parts of the region. Also, device maintenance costs and stringent regulatory product approval procedures are further predicted to hamper the market growth.
The Asia Pacific is estimated to grow significantly during the forecast period, and the regional market growth is attributed to the improving healthcare infrastructure, growing population, advances in science and technology, and development of minimally invasive treatment procedures.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| CAGR | 9.18% |
| Segments Covered | By Product and Region |
| Various Analyses Covered | Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
| Countries Covered | India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, the Philippines, Indonesia, Singapore, and the Rest of APAC. |
| Market Leaders Profiled | Abbott Laboratories, Boston Scientific Corporation, Cardinal Health Inc., GE Healthcare, WL Gore & Associates Inc., Medtronic PLC, Biotronik, Siemens Healthineers AG, Canon Medical Systems Corporation, Edwards Lifesciences, B. Braun Melsungen AG, and Livanova |
REGIONAL ANALYSIS
China held the largest APAC cardiovascular devices market share in 2025 and is likely to continue its growth during the forecast period. Technological advancements in the healthcare sector, increasing research and development activities, the growing geriatric population, and the increasing prevalence of cardiovascular diseases are propelling the market in the country.
Similarly, the Indian cardiovascular devices market is expected to have a promising share in the APAC market. In India, the prevalence of CVDs is substantially higher. Therefore, government initiatives that promote market expansion are encouraging. However, sophisticated private specialty hospitals in major cities across the country offer effective CVD therapy. In addition, various private hospitals such as Apollo and Fortis and hospitals run by government entities have CVD treatment capabilities in India.
KEY MARKET PLAYERS
A few of the prominent companies operating in the APAC cardiovascular devices market include
- Abbott Laboratories
- Boston Scientific Corporation
- Cardinal Health Inc.
- GE Healthcare
- WL Gore & Associates Inc.
- Medtronic PLC
- Biotronik
- Siemens Healthineers AG
- Canon Medical Systems Corporation
- Edwards Lifesciences
- B. Braun Melsungen AG
- Livanova
MARKET SEGMENTATION
This research report on the Asia Pacific cardiovascular devices market has been segmented and sub-segmented into the following categories.
By Product
- Diagnostic and Monitoring
- ECG
- Holter Monitors
- Event Monitors
- Implantable Loop Recorders
- Echocardiogram
- Pet Scan
- MRI
- Cardiac CT
- Doppler Fetal Monitors
- Surgical Devices
- Pacemakers
- Stents
- Catheters and accessories
- Guidewires
- Cannulae
- Electrosurgical Procedures
- Valves
- Occlusion Devices
By Country
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC